You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMaprotiline
Accession NumberDB00934  (APRD00747)
TypeSmall Molecule
GroupsApproved
DescriptionMaprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Structure
Thumb
Synonyms
Maprotilina
Maprotilinum
Maprotylina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ludiomil Tab 10mgtablet10 mgoralNovartis Pharmaceuticals Canada Inc1985-12-312003-07-29Canada
Ludiomil Tab 25mgtablet25 mgoralNovartis Pharmaceuticals Canada Inc1976-12-312001-07-30Canada
Ludiomil Tab 50mgtablet50 mgoralNovartis Pharmaceuticals Canada Inc1976-12-312001-07-30Canada
Ludiomil Tab 75mgtablet75 mgoralNovartis Pharmaceuticals Canada Inc1976-12-312000-08-02Canada
Novo-maprotiline - Tab 10mgtablet10 mgoralNovopharm Limited1995-12-312005-08-10Canada
PMS-maprotilinetablet75 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilinetablet10 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilinetablet25 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilinetablet50 mgoralPharmascience IncNot applicableNot applicableCanada
Teva-maprotilinetablet75 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Teva-maprotilinetablet50 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Teva-maprotilinetablet25 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Maprotiline Hydrochloridetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.1988-10-03Not applicableUs
Maprotiline Hydrochloridetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.1988-10-03Not applicableUs
Maprotiline Hydrochloridetablet, film coated75 mg/1oralMylan Pharmaceuticals Inc.1988-10-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DeprileptNot Available
LudiomilNot Available
PsymionNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Maprotiline Hydrochloride
Thumb
  • InChI Key: NZDMFGKECODQRY-UHFFFAOYSA-N
  • Monoisotopic Mass: 313.15972748
  • Average Mass: 313.864
DBSALT000482
Categories
UNII2U1W68TROF
CAS number10262-69-8
WeightAverage: 277.4033
Monoisotopic: 277.183049741
Chemical FormulaC20H23N
InChI KeyQSLMDECMDJKHMQ-UHFFFAOYSA-N
InChI
InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
IUPAC Name
methyl(3-{tetracyclo[6.6.2.0²,⁷.0⁹,¹⁴]hexadeca-2,4,6,9,11,13-hexaen-1-yl}propyl)amine
SMILES
CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassAnthracenes
Sub ClassNot Available
Direct ParentAnthracenes
Alternative Parents
Substituents
  • Anthracene
  • Tetralin
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.
PharmacodynamicsMaprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline reuptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.
Mechanism of actionMaprotiline exerts its antidepressant action by inhibition of presynaptic uptake of catecholamines, thereby increasing their concentration at the synaptic clefts of the brain. In single doses, the effect of maprotiline on the EEG revealed a rise in the alpha-wave density, a reduction of the alpha-wave frequency and an increase in the alpha-wave amplitude. However, as with other tricyclic antidepressants, maprotiline lowers the convulsive threshold. Maprotiline acts as an antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and hetero-receptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Maprotiline is also a moderate peripheral α1 adrenergic antagonist, which may explain the occasional orthostatic hypotension reported in association with its use. Maprotiline also inhibits the amine transporter, delaying the reuptake of noradrenaline and norepinephrine. Lastly, maprotiline is a strong inhibitor of the histamine H1 receptor, which explains its sedative actions.
Related Articles
AbsorptionSlowly, but completely absorbed from the GI tract following oral administration.
Volume of distribution

Maprotiline and its metabolites may be detected in the lungs, liver, brain, and kidneys; lower concentrations may be found in the adrenal glands, heart and muscle. Maprotiline is readily distributed into breast milk to similar concentrations as those in maternal blood.

Protein binding88%
Metabolism

Hepatic. Maprotiline is metabolized by N-demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives. It is slowly metabolized primarily to desmethylmaprotiline, a pharmacologically active metabolite. Desmethylmaprotiline may undergo further metabolism to maprotiline-N-oxide.

SubstrateEnzymesProduct
Maprotiline
demethylmaprotilineDetails
Route of eliminationApproximately 60% of a single orally administered dose is excreted in urine as conjugated metabolites within 21 days; 30% is eliminated in feces.
Half lifeAverage ~ 51 hours (range: 27-58 hours)
ClearanceNot Available
ToxicityLD50=~900 mg/kg (Orally in rats); LD50=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9903
Caco-2 permeable+0.7214
P-glycoprotein substrateSubstrate0.7836
P-glycoprotein inhibitor IInhibitor0.7667
P-glycoprotein inhibitor IIInhibitor0.7206
Renal organic cation transporterInhibitor0.6502
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5216
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.855
Ames testNon AMES toxic0.7713
CarcinogenicityNon-carcinogens0.9204
BiodegradationNot ready biodegradable0.8913
Rat acute toxicity2.5307 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7016
hERG inhibition (predictor II)Inhibitor0.8652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • American therapeutics inc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral75 mg
Prices
Unit descriptionCostUnit
Novo-Maprotiline 75 mg Tablet1.54USD tablet
Maprotiline HCl 75 mg tablet1.25USD tablet
Novo-Maprotiline 50 mg Tablet1.13USD tablet
Maprotiline 75 mg tablet0.91USD tablet
Maprotiline HCl 50 mg tablet0.86USD tablet
Maprotiline 50 mg tablet0.79USD tablet
Maprotiline HCl 25 mg tablet0.73USD tablet
Maprotiline 25 mg tablet0.69USD tablet
Novo-Maprotiline 25 mg Tablet0.6USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point93 °CPhysProp
water solubilitySlightly solubleNot Available
logP5.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00015 mg/mLALOGPS
logP4.89ALOGPS
logP4.37ChemAxon
logS-6.3ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.3 m3·mol-1ChemAxon
Polarizability33.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0f6x-9560000000-f263c228ecd4df5d7e73View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AA21
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (64.8 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Maprotiline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Maprotiline is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe serum concentration of Maprotiline can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Maprotiline.
AcepromazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Maprotiline.
AcetophenazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Maprotiline.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Maprotiline.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Maprotiline.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Maprotiline.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Maprotiline.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Maprotiline.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Maprotiline.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Maprotiline.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Maprotiline.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Maprotiline.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Maprotiline.
AmiodaroneMaprotiline may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Maprotiline can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Maprotiline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Maprotiline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Maprotiline.
AmoxapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amperozide.
AnagrelideMaprotiline may increase the QTc-prolonging activities of Anagrelide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Maprotiline.
AripiprazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Maprotiline.
ArtemetherMaprotiline may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Maprotiline can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Maprotiline.
AsenapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Maprotiline.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Maprotiline.
AtomoxetineThe metabolism of Maprotiline can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Maprotiline.
AzaperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Azaperone.
AzelastineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Maprotiline.
AzithromycinMaprotiline may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Maprotiline can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Maprotiline.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Maprotiline.
BedaquilineMaprotiline may increase the QTc-prolonging activities of Bedaquiline.
BenmoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benmoxin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Maprotiline.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Maprotiline.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Maprotiline.
BetaxololThe metabolism of Maprotiline can be decreased when combined with Betaxolol.
BifeprunoxThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bifeprunox.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Maprotiline.
BortezomibThe metabolism of Maprotiline can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Maprotiline.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Maprotiline.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
BrimonidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Maprotiline.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Maprotiline.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Maprotiline.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Maprotiline.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Maprotiline.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Maprotiline.
BupropionThe metabolism of Maprotiline can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Maprotiline.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Maprotiline.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Maprotiline.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Maprotiline.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Maprotiline.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Maprotiline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Maprotiline.
CaffeineThe metabolism of Maprotiline can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Maprotiline.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Maprotiline.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Maprotiline.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Maprotiline.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Maprotiline.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Maprotiline.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Maprotiline.
CariprazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.
CaroxazoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Caroxazone.
CelecoxibThe metabolism of Maprotiline can be decreased when combined with Celecoxib.
CeritinibMaprotiline may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Maprotiline.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Maprotiline.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Maprotiline.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Maprotiline.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Maprotiline.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Maprotiline.
ChloroquineMaprotiline may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Maprotiline can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Maprotiline can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Maprotiline.
CholecalciferolThe metabolism of Maprotiline can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Maprotiline.
CimetidineThe metabolism of Maprotiline can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Maprotiline can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Maprotiline.
CiprofloxacinMaprotiline may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideMaprotiline may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Maprotiline.
CitalopramThe risk or severity of adverse effects can be increased when Maprotiline is combined with Citalopram.
CitalopramThe metabolism of Maprotiline can be decreased when combined with Citalopram.
ClarithromycinMaprotiline may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Maprotiline can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Maprotiline.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Maprotiline.
ClobazamThe metabolism of Maprotiline can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Maprotiline.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Maprotiline.
ClomipramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clomipramine.
ClomipramineThe metabolism of Maprotiline can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Maprotiline.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Maprotiline.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Maprotiline.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Maprotiline.
ClotrimazoleThe metabolism of Maprotiline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clozapine.
ClozapineThe metabolism of Maprotiline can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Maprotiline can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Maprotiline.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Maprotiline.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Maprotiline.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Maprotiline.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Maprotiline.
CrizotinibMaprotiline may increase the QTc-prolonging activities of Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Maprotiline.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Maprotiline.
Cyproterone acetateThe serum concentration of Maprotiline can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Maprotiline.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Maprotiline.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Maprotiline.
DantroleneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Maprotiline.
DapiprazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Maprotiline.
DarifenacinThe metabolism of Maprotiline can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Maprotiline can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Maprotiline.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Maprotiline.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Maprotiline.
DeferasiroxThe serum concentration of Maprotiline can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Maprotiline can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Maprotiline.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Maprotiline.
DesipramineThe metabolism of Maprotiline can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Maprotiline.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Maprotiline.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Maprotiline.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Maprotiline.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Maprotiline.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Maprotiline.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Maprotiline.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Maprotiline.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Maprotiline.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Maprotiline.
DifenoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Maprotiline.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Maprotiline.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Maprotiline.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Maprotiline.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Maprotiline.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Maprotiline.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Maprotiline.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Maprotiline.
DimenhydrinateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Maprotiline can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Maprotiline.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Maprotiline.
DisopyramideMaprotiline may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Maprotiline.
DofetilideMaprotiline may increase the QTc-prolonging activities of Dofetilide.
DolasetronMaprotiline may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Maprotiline.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Maprotiline.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Maprotiline.
DoxepinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Maprotiline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
DoxylamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Maprotiline.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
DronedaroneMaprotiline may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Maprotiline can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Maprotiline.
DuloxetineThe metabolism of Maprotiline can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Maprotiline.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Maprotiline.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Maprotiline.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Maprotiline.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.
EliglustatMaprotiline may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Maprotiline can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Maprotiline.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Maprotiline.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Maprotiline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Maprotiline.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Maprotiline.
ErythromycinMaprotiline may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Maprotiline is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Maprotiline.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Maprotiline.
EstriolThe serum concentration of Estriol can be increased when it is combined with Maprotiline.
EstroneThe serum concentration of Estrone can be increased when it is combined with Maprotiline.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Maprotiline.
EthanolMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Maprotiline.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Maprotiline.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Maprotiline.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Maprotiline.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Maprotiline.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Maprotiline.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Maprotiline.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Maprotiline.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Maprotiline.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Maprotiline.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Maprotiline.
EtoperidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Maprotiline.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Maprotiline.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Maprotiline.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Maprotiline.
EzogabineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Maprotiline.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Maprotiline.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Maprotiline.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Maprotiline.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Maprotiline.
FlecainideMaprotiline may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Maprotiline.
FlunarizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Maprotiline.
FluoxetineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluoxetine.
FluoxetineThe metabolism of Maprotiline can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.
FluspirileneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Maprotiline.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Maprotiline.
FluvoxamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluvoxamine.
FluvoxamineThe metabolism of Maprotiline can be decreased when combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Maprotiline.
FrovatriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Frovatriptan.
FurazolidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Furazolidone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Maprotiline.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Maprotiline is combined with gabapentin enacarbil.
Gadobenic acidMaprotiline may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Maprotiline.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Maprotiline.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Maprotiline.
GemifloxacinMaprotiline may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Maprotiline.
GoserelinMaprotiline may increase the QTc-prolonging activities of Goserelin.
GranisetronMaprotiline may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Maprotiline.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Maprotiline.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Maprotiline.
GuanfacineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Maprotiline.
HaloperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Haloperidol.
HaloperidolThe metabolism of Maprotiline can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Maprotiline.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Maprotiline.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Maprotiline.
HydracarbazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Hydracarbazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Maprotiline.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Maprotiline.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
HydroxyzineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Maprotiline.
IbutilideMaprotiline may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Maprotiline.
IloperidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Maprotiline.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Maprotiline.
ImipramineThe metabolism of Maprotiline can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Maprotiline.
IndalpineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Indalpine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Maprotiline.
IndinavirThe metabolism of Maprotiline can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Maprotiline.
IproclozideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproniazid.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Maprotiline.
IsocarboxazidThe risk or severity of adverse effects can be increased when Maprotiline is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Maprotiline.
IsoniazidThe metabolism of Maprotiline can be decreased when combined with Isoniazid.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Maprotiline.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Maprotiline.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Maprotiline.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Maprotiline.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Maprotiline.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Maprotiline.
KetoconazoleThe metabolism of Maprotiline can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Maprotiline.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Maprotiline.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Maprotiline.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Maprotiline.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Maprotiline.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Maprotiline.
LenvatinibMaprotiline may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideMaprotiline may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Maprotiline.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Maprotiline.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Maprotiline.
LevocabastineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levodopa.
LevofloxacinMaprotiline may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Maprotiline.
LevomilnacipranThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.
LidocaineThe metabolism of Maprotiline can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Maprotiline.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Maprotiline.
LithiumThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Maprotiline.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Maprotiline.
LopinavirMaprotiline may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Maprotiline can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Maprotiline.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.
LorcaserinThe metabolism of Maprotiline can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Maprotiline.
LoxapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Maprotiline is combined with Lu AA21004.
LumefantrineMaprotiline may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Maprotiline can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mebanazine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Maprotiline.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Maprotiline.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Maprotiline.
MelperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Maprotiline.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.
MesoridazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.
MethadoneMaprotiline may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Maprotiline can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Maprotiline.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Maprotiline.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Maprotiline.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Maprotiline.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Maprotiline.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Maprotiline.
MethsuximideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.
Methylene blueThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Maprotiline.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Maprotiline.
MetoclopramideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Maprotiline.
MetoprololThe metabolism of Maprotiline can be decreased when combined with Metoprolol.
MetyrosineMaprotiline may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Maprotiline can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Maprotiline.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Maprotiline.
MifepristoneMifepristone may increase the QTc-prolonging activities of Maprotiline.
MilnacipranThe risk or severity of adverse effects can be increased when Maprotiline is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Maprotiline.
MirabegronThe metabolism of Maprotiline can be decreased when combined with Mirabegron.
MirtazapineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Maprotiline.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Maprotiline.
MoclobemideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Moclobemide.
MolindoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Maprotiline.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.
MoxifloxacinMaprotiline may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Maprotiline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
NabiloneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Maprotiline.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Maprotiline.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Maprotiline.
NaratriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Naratriptan.
NefazodoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Maprotiline.
NevirapineThe metabolism of Maprotiline can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nialamide.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Maprotiline.
NicardipineThe metabolism of Maprotiline can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Maprotiline.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Maprotiline.
NilotinibThe metabolism of Maprotiline can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Maprotiline.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Maprotiline.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Maprotiline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Maprotiline.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Maprotiline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Maprotiline.
OctamoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Octamoxin.
OfloxacinMaprotiline may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Maprotiline.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Maprotiline.
OndansetronThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Maprotiline.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Maprotiline.
OrphenadrineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Maprotiline.
OsanetantThe risk or severity of adverse effects can be increased when Maprotiline is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Maprotiline.
OsimertinibThe serum concentration of Maprotiline can be decreased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Maprotiline.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Maprotiline.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Maprotiline.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Maprotiline.
PaliperidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Maprotiline.
PanobinostatMaprotiline may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Maprotiline can be decreased when combined with Panobinostat.
ParaldehydeMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Maprotiline.
PargylineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Paroxetine.
ParoxetineThe metabolism of Maprotiline can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Maprotiline.
Peginterferon alfa-2bThe serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineMaprotiline may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Maprotiline.
PerampanelThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perampanel.
PerflutrenMaprotiline may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Maprotiline.
PhenelzineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pheniprazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Maprotiline.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Maprotiline.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Maprotiline.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenoxypropazine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Maprotiline.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Maprotiline.
PimozideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipotiazine.
PirlindoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Maprotiline.
PivhydrazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Maprotiline.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Maprotiline.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Maprotiline.
PramipexoleMaprotiline may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Maprotiline.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Maprotiline.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Maprotiline.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Maprotiline.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Maprotiline.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Maprotiline.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Maprotiline.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Maprotiline.
PrimaquineMaprotiline may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Maprotiline.
ProcainamideMaprotiline may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Maprotiline.
ProcarbazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Maprotiline.
PromazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promazine.
PromazineThe metabolism of Maprotiline can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promethazine.
PropafenoneMaprotiline may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Maprotiline.
PropericiazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Maprotiline.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Maprotiline.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Maprotiline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Maprotiline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Maprotiline.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Maprotiline.
QuetiapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Quetiapine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Maprotiline.
QuinidineThe metabolism of Maprotiline can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Maprotiline.
QuinineThe metabolism of Maprotiline can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Maprotiline.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Maprotiline.
RanolazineThe metabolism of Maprotiline can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Maprotiline.
RemoxiprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Reserpine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Maprotiline.
RifampicinThe metabolism of Maprotiline can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Maprotiline.
RisperidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Maprotiline.
RitonavirThe metabolism of Maprotiline can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Maprotiline.
RizatriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rizatriptan.
RolapitantThe metabolism of Maprotiline can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Maprotiline.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Maprotiline.
RopiniroleMaprotiline may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Maprotiline can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Maprotiline.
RotigotineMaprotiline may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Maprotiline.
SafrazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Safrazine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Maprotiline.
SaquinavirMaprotiline may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Maprotiline.
SelegilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Maprotiline.
SertindoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.
SertralineThe metabolism of Maprotiline can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Maprotiline.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Maprotiline.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Maprotiline.
SimeprevirThe metabolism of Maprotiline can be decreased when combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Maprotiline.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Maprotiline.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Maprotiline.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Maprotiline.
SotalolMaprotiline may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Maprotiline.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Maprotiline.
StiripentolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.
SulfisoxazoleMaprotiline may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Maprotiline.
SuvorexantThe risk or severity of adverse effects can be increased when Maprotiline is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Maprotiline.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Maprotiline.
TapentadolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Maprotiline.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Maprotiline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Maprotiline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Maprotiline.
TelavancinMaprotiline may increase the QTc-prolonging activities of Telavancin.
TelithromycinMaprotiline may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Maprotiline.
TenofovirThe metabolism of Maprotiline can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Maprotiline can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Maprotiline.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Maprotiline.
ThalidomideMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Maprotiline.
TheophyllineThe metabolism of Maprotiline can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Maprotiline.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Maprotiline.
ThioproperazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Maprotiline.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Maprotiline.
TiclopidineThe metabolism of Maprotiline can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Maprotiline.
TimololThe serum concentration of Timolol can be increased when it is combined with Maprotiline.
TipranavirThe metabolism of Maprotiline can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Maprotiline.
ToloxatoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Toloxatone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Maprotiline.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Maprotiline.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Maprotiline.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Maprotiline.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Maprotiline.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tranylcypromine.
TranylcypromineThe metabolism of Maprotiline can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Maprotiline.
TrazodoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.
TrifluoperazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Maprotiline.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Maprotiline.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Maprotiline.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Maprotiline.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Maprotiline.
VandetanibMaprotiline may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Maprotiline.
VemurafenibThe serum concentration of Maprotiline can be increased when it is combined with Vemurafenib.
VemurafenibMaprotiline may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Maprotiline.
VenlafaxineThe metabolism of Maprotiline can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Maprotiline.
VigabatrinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Maprotiline.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Maprotiline.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Maprotiline.
VortioxetineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Maprotiline.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Maprotiline.
ZiconotideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Maprotiline.
ZimelidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziprasidone.
ZiprasidoneThe metabolism of Maprotiline can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Maprotiline.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Maprotiline.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Maprotiline.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Maprotiline.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Maprotiline.
ZotepineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Limit caffeine intake.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Saba W, Valette H, Schollhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M: [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse. 2007 Jan;61(1):17-23. [PubMed:17068778 ]
  2. Arai S, Morita K, Kitayama S, Kumagai K, Kumagai M, Kihira K, Dohi T: Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics. Brain Res. 2003 Feb 21;964(1):83-90. [PubMed:12573515 ]
  3. Cloonan SM, Drozgowska A, Fayne D, Williams DC: The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. 2010 Mar;51(3):523-39. doi: 10.3109/10428190903552112. [PubMed:20141432 ]
  4. Dronjak S, Spasojevic N, Gavrilovic L, Varagic V: Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats. Neuro Endocrinol Lett. 2007 Oct;28(5):614-20. [PubMed:17984940 ]
  5. Mochizucki D: Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004 Oct;19 Suppl 1:S15-9. [PubMed:15378668 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628 ]
  2. Cavero I, Lefevre-Borg F, Roach AG: Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol. 1981 Sep;74(1):143-8. [PubMed:6115693 ]
  3. Kanba S, Richelson E: Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res. 1984 Jun 18;304(1):1-7. [PubMed:6146381 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein group
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827-9. [PubMed:7221567 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827-9. [PubMed:7221567 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Brachtendorf L, Jetter A, Beckurts KT, Holscher AH, Fuhr U: Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9. [PubMed:12071336 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]
  2. Eap CB, Cuendet C, Baumann P: Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 1988 Feb;337(2):220-4. [PubMed:3368020 ]
  3. Lynn K, Braithwaite R, Dawling S, Rosser R: Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis. Eur J Clin Pharmacol. 1981 Jan;19(1):73-7. [PubMed:7461027 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23